Loading
Created cord blood-derived CAR-NK cells, the first off-the-shelf CAR cell therapy to show remissions in lymphoma.
Katy Rezvani led the development and first-in-human trial of CD19-directed CAR natural killer cells derived from cord blood, which produced remissions in most patients with relapsed CLL and lymphoma without cytokine release syndrome or graft-versus-host disease, establishing NK cells as an allogeneic platform. Her laboratory engineers NK cells against solid tumour and myeloid targets and she directs the cell therapy programme at MD Anderson.
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Diffuse large B-cell lymphoma and the tag cell-therapy.
Shares MD Anderson Cancer Center, CD19, Diffuse large B-cell lymphoma and the tag cell-therapy.
Shares MD Anderson Cancer Center, CD19, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, CD19 and the tag cell-therapy.
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.